Abstract
The introduction in the 1980s of cyclosporine and monoclonal antibodies represented a major therapeutic advance in solid organ transplantation. The United Network for Organ Sharing (UNOS) has recently released the 1- and 2-year graft and patient survival rates for solid organ transplants (1). These survival rates are illustrated in Table 1. Currently, there are a number of promising new immunosuppressive agents on the horizon, and it appears likely that further advances will be made in our ability to control the immune response (2,3). A dynamic interaction exists between basic immunology and clinical transplantation. Advances in immunobiology have resulted in a better understanding of the immunological events involved in the recognition of and response to transplant antigens and have led to a better understanding of the action of various immunosuppressive agents. This chapter reviews the mechanisms involved in the immune response, how currently used immunosuppressive agents act, the possible role for future immunosuppressive drugs, the current approach to clinical immunosuppressive therapy, and the diagnosis and treatment of acute rejection.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Annual Report of the U. S. Scientific Registry of Transplant Recipients and the Organ Procurement and Transplant Network, Executive Summary. U.S. Department of Health and Human Services, Library of Congress Catalog Card Number 93–060966, p 22, 1993.
First MR: Transplantation in the nineties. Transplantation 53: 1–11, 1992.
First MR: New immunosuppressive drugs. Am J Kidney Dis 19: 3–9, 1992.
Thorsby E: Structure and function of HLA-molecules. Transplant Proc 19: 29–35, 1987.
Strom TB, Tilney NL: Immunobiology and immunopharmacology of graft rejection. In: RW Schrier, CW Gottschalk, eds, Diseases of the Kidney. Little, Brown, Boston, pp 2879–2910, 1993.
Weiss A, Imboden J, Hardy K, Manger B, Terhorst C, Stobo J: The role of the antigen receptor complex in T-cell activation. Annu Rev Immunol 4: 593–619, 1986.
Williams JM, DeLoria D, Hansen JA, Dinarello CA, Loertscher R, Shapiro HM, Strom TB: The events of primary T cell activation can be staged by use of sepharose bound anti-T3 (64.1) monoclonal antibody and interleukin-1. J Immunol 135: 2249–2255, 1985.
Moore RN, Oppenheim JJ, Farrar JJ, Carter CS, Waheed A, Shadduck RK: Production of LAF (IL-1) by macrophages activated by colony stimulating factors. J Immunol 125: 1302 1305, 1980.
Smith KA, Lachman LB, Oppenheim JJ, Favata MF: The functional relationship of the interleukins. J Exp Med 151: 1551–1556, 1980.
Farrar WL, Johnson HM, Farrar JJ: Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin-2. J Immunol 126: 1120–1125, 1981.
Inaba K, Granelli-Piperno G, Steinman RM: Dendritic cells induce T lymphocytes to release B cell-stimulating factors by an interleukin-2-dependent mechanism. J Exp Med 158: 2040–2057, 1983.
Cantrell DA, Smith KA: The interleukin-2 T cell system: a new cell growth model. Science 224: 1312–1316, 1984.
Moscovitch-Lopatin M, Petrillo RJ, Pankewycz O, Hadro E, Bleackley CR, Strom TB, Wieder KJ: Interleukin-2 counteracts the inhibition of cytotoxic T lymphocytes by cholera toxin in vitro and in vivo. Eur J Immunol 21: 1439–1444, 1991.
Kelley VE, Fiers W, Strom TB: Cloned human interferon-gamma, but not interferon-beta or -alpha, induces expression of HLA-DR determinants by fetal monocytes and myeloid leukemia cell lines. J Immunol 132: 240–245, 1984.
Pober JS, Gimbrone MA, Cotran RS, Reiss CS, Burakoff SJ, Fiers W, Ault KA: Ia expression by vascular endothelium is inducible by activated T cells and by human gamma-interferon. J Exp Med 157: 1339–1353, 1983.
Fabre JW, Milton AD, Spencer S, Settaf A, Houssin D: Regulation of alloantigen expression in different tissues. Transplant Proc 19: 45–49, 1987.
Lu CY, Sicher SC, Vazquez MA: Prevention and treatment of renal allograft rejection: new therapeutic approaches and new insights into established therapies. J Am Soc Nephrol 4: 1239–1256, 1993.
Hall BM: Cellular infiltrates in allografts. Transplant Proc 19: 50–56, 1987.
Han J, Thompson B, Beutler B: Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 172: 391–394, 1990.
Lee SW, Tsou AP, Chan H, Thomas J, Petrie K, Euglei EM, Allison AC: Glucorticoids selectively inhibit the transcription of the interleukin-1 beta gene and decrease the stability of interleukin-1 beta gene mRNA. Proc Natl Acad Sci USA 85: 1204–1208, 1988.
Vacca A, Felli MP, Farina AR, Martinotti S, Maroder M, Screpanti I, Meco D, Petrangeli E, Frati L, Golino A: Glucorticoid receptor-mediated suppression of the interleukin-2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J Exp Med 175: 637–646, 1992.
Northrop JP, Crabtree GR, Mattila PS: Negative regulation of interleukin-2 transcription by the glucocorticoid receptor. J Exp Med 175: 1235–1245, 1992.
Zimmer T, Jones PP: Combined effects of tumor necrosis factor-alpha, prostaglandin E2, and corticosterone on induced la expression on murine macrophages. J Immunol 145: 1167–1175, 1991.
Politis AD, Sivo J, Driggers PH, Ozato K, Vogel SN: Modulation of interferon consensus sequence binding protein mRNA in murine peritoneal macrophages: induction by INF-y and down-regulation by INF-a, dexamethasone, and protein kinase inhibitors. J Immunol 148: 801–807, 1992.
Knudsen PJ, Dinarello CA, Strom TB: Glucorticoids inhibit transcription and post-transcription of interleukin-1. J Immunol 139: 4129–4134, 1987.
Zanker B, Walz G, Wieder KJ, Strom TB: Evidence that glucocorticoids block expression of the human interleukin6 gene by accessory cells. Transplantation 49: 183–185, 1990.
Elion GB: Biochemistry and pharmacology of purine analogues. Fed Proc 26: 898–904, 1967.
Rossi SJ, Schroeder TJ, Hariharan S, First MR: Prevention and management of the adverse effects associated with immunosuppressive therapy. Drug Safety 9: 104–131, 1993.
First MR, Alexander JW, Wadhwa N, Penn I, Munda R, Fidler JP, Weisskittel P: The use of low dose cyclosporine, azathioprine and prednisone in renal transplantation. Transplant Proc 18 (Suppl 1): 132–135, 1986.
Levine LA, Richie JP: Urological complications of cyclophosphamide. J Uro1141:1063–1069, 1989.
First MR: Renal allograft survival after 1 and 10 years: Comparison between pre-cyclosporin and cyclosporin data. Nephrol Dial Transplant 9: 90–97, 1993.
Schreiber SL: Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251: 283–287, 1991.
Walsh CT, Zydowsky LD, McKeon FD: Cyclosporin A, the cyclophilin class of peptidylprolyl isomerases, and blockade of T cell signal transduction. J Biol Chem 267: 13115–13118, 1992.
Feutren G, Mihatsch MJ: Risk factors for cyclosporineinduced nephropathy in patients with autoimmune disease. N Engl J Med 326: 1654–1660, 1992.
Myers B: Cyclosporine nephrotoxicity. Kidney Int 30: 964974, 1986.
Curtis J, Luke R, Jones P, Diethelm A: Hypertension in cyclosporine renal transplant recipients is sodium dependent. Am J Med 85: 134–138, 1988.
First MR, Neylan JF, Rocher LL, Tejani A: Hypertension after renal transplantation. J Am Soc Nephrol 4 (Suppl 1): S30 - S36, 1994.
Kahan BD: Cyclosporine nephrotoxicity: pathogenesis, prophylaxis, therapy, and prognosis. Am J Kidney Dis 8: 323–331, 1986.
Kahan BD: Cyclosporine. N Engl J Med 321: 1725–1738, 1989.
Cosimi AB, Delmonico FL: Antilymphocyte antibody therapy. In: JF Burdick, LC Rascusen, K Solez, GM Williams, eds, Kidney Transplant Rejection: Diagnosis and Treatment. Marcel Dekker, New York, pp 541–565, 1992.
Filo RS, Smith EJ, Leapman SB: Therapy of acute cadaveric renal allograft rejection with adjunctive antithymocyte globulin. Transplantation 30: 444–449, 1980.
Streem SB, Novick AC, Braun WE, Steinmuller D, Greenstreet R: Low-dose maintenance prednisone and antilymphoblast globulin for the treatment of acute rejection. Transplantation 35: 420–424, 1983.
Diflo T, Monaco AP: Clinical immunosuppressive drug therapy. In: AW Thomson, GRD Catto, eds, Immunology of Renal Transplantation. Edward Arnold, London, pp 255–263, 1993.
O’Connelll PJ, Corpier CL, Steele A, Strom T: Monoclonal antibody therapy. In: AW Thomson, GRD Catto, eds, Immunology of Renal Transplantation. Edward Arnold, London, pp 281–302, 1993.
Cosimi AB, Colvin RB, Burton RC, Rubin RH, Goldstein G, Kung PC, Hansen WP, Delmonico FL, Russel PS: Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 305: 308–314, 1981.
Cosimi AB: OKT3: first-dose safety and success. Nephron 46: 12–18, 1987.
Schroeder TJ, First MR: Monoclonal antibodies in organ transplantation. Am J Kidney Dis 23: 138–147, 1994.
Ortho Multicenter Study Group: A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313: 337–342, 1985.
Thistlethwaite JR, Gaber AO, Haag BW, Arouson AJ, Broelsch CE, Stuart JK, Stuart FP: OKT3 treatment of steroid-resistant renal allograft rejection. Transplantation 43: 176–184, 1987.
Norman DJ, Shield CF: OKT3: first-line therapy or last option? Transplant Proc 18: 949–953, 1986.
Norman DJ, Barry JM, Bennett WM, Leone M, Henell K, Funnell B, Hubert B: The use of OKT3 in cadaveric renal transplantation that is unresponsive to conventional anti-rejection therapy. Am J Kidney Dis 11: 90–93, 1988.
Schroeder TJ, Weiss MA, Smith RD, Stephens GW, Carey M, First MR: The efficacy of OKT3 in vascular rejection. 51: 312–315, 1991.
Schroeder TJ, First MR, Mansour ME, Alexander JW, Penn I: Prophylactic use of OKT3 in immunological high risk renal transplant recipients. Am J Kidney Dis 14 (Suppl 2): 14–18, 1989.
Cardella CJ, Blake P, Cattran D, Cole E: Prophylactic OKT3 in renal retransplantation. Transplant Proc 21: 3373–3374, 1989.
Benvensky AJ, Cohen D, Stegall MD, Hardy MA: Improved results using OKT3 as induction immunosuppression in cadaver kidney recipients. Transplantation 49: 321–327, 1990.
Norman DJ, Kahana L, Stuart FP, Thistlethwaite JR, Shield CF, Monaco A, Dehlinger J, Wu SC, Vanhorn A, Haverty TP: A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 55: 44–50, 1993.
Abram000wicz D, Schandene L, Goldman M, Crusiaux A, Vereestraeten P, De Pauw L, Wybran J, Kinnaert P, Dupont E, Toussaint C: Release of tumor necrosis factor-alpha, interleukin-2 and interferon-gamma in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Trsansplantation 47: 606–608, 1989.
Chatenoud L, Reuter A, Legendre C, Gevaert Y, Kreis H, Franchimont P, Bach JF: Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N Engl J Med 320: 1420–1421, 1989.
Suthanthiran M, Fotino M, Giggio RR, Cheigh JS, Stenzel KH: OKT3 associated adverse reactions: mechanistic basis and therapeutic options. Am J Kidney Dis 14 (Suppl 2): 3944, 1989.
First MR, Schroeder TJ, Hariharan S: The OKT3-induced cytokine release syndrome: renal effects (cytokine nephropathy). Transplant Proc 25 (Suppl 1): 25–26, 1993.
Chatenoud L, Legendre C, Ferran C, Bach J, Kreis H: Corticosteroid inhibition of the OKT3-induced cytokine-release syndrome: dosage and kinetic prerequisites. Transplantation 51: 334–338, 1991.
First MR, Schroeder TJ, Hariharan S, Alexander JW, Weiskittel P: The effect of indomethacin on the febrile response following OKT3 therapy. Transplantation 53: 91–94, 1992.
Alegre M, Gastadello K, Abramoowicz D, Kinnaert P, Vereerstraeten P, De Pauw L, Vandenabeele P, Moser M, Leo O, Goldman M. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome. Transplantation 52: 674–679, 1991.
Chatenoud L: OKT3-induced cytokine-release syndrome: preventive effect of anti-tumor necrosis factor monoclonal antibody. Transplant Proc 25 (Suppl 1): 47–51, 1993.
Jaffers GJ, Fuller TC, Cosimi AB, Russell PS, Winn HJ, Colvin RB: Monoclonal antibody therapy: anti-idiotypic and non-anti-idiotypic antibodies to OKT3 aristing despite intense immunosuppression. Transplantation 41: 572–578, 1986.
Chatenoud L, Baudrihaye MF, Kreis H, Goldstein G, Bach JF: Restriction of the human in vivo response against the mouse monoclonal antibody OKT3. J Immunol 137: 830–838, 1986.
Nelson PW, Jaffers GJ, Fuller TC, Cosimi AB, Colvin RB: Reduction of immune response to OKT3 monoclonal antibody. Transplant Proc 17: 644–645, 1985.
Schroeder TJ, First MR, Mansour ME, Hurtubise PE, Hariharan S, Ryckman FC, Munda R, Melvin DB, Penn I, Balistreri WF, Alexander JW: Antimurine antibody formation following OKT3 therapy. Transplantation 49: 48–51, 1990.
Hricik DE, Mayes JT, Schulak JA: Inhibition of anti-OKT3 antibody generation by cyclosporine: results of a prospective randomized trial. Transplantation 50: 237–240, 1990.
First MR, Schroeder TJ, Hurtubise PE, Mansour ME, Penn I, Munda R, Balistreri WF, Alexander JW, Melvin DB, Fidler JP, Ryckman FC, Brunson ME: Successful retreatment of allograft rejection with OKT3. Transplantation 47: 88–91, 1989.
Kahan BD: Synergism: how assessed and how achieved. Clin Transplantation 5: 534–539, 1991.
Groth CG, Ohlman S, Gannedahl G, Ericzon BG: New immunosuppressive drugs in transplantation. Transplant Proc 25: 2681–2683, 1993.
Morris RE: Primer on new small molecule immunosuppressants. Transplant Soc Bull 1: 15–21, 1993.
Kamata K, Okubo M, Ishigamori E, Masaki Y, Uchida H, Watanabe K, Kashiwagi N: Immunosuppressive effect of bredinin on cell-mediated and humoral immune reactions in experimental animals. Transplantaion 35: 144–145, 1983.
Turka LA, Dayton J, Sinclair G, Thompson CB, Mitchell BS: Guanine ribonucleotide depletion inhibits T cell activation: mechanism of action of the immunosuppressive drug mizoribine. J Clin Invest 87: 940–948, 1991.
Dayton JS, Turka LA, Thompson CB, Mitchell BS: Comparison of the effects of mizoribine with those of azathioprine, 6mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism. Mol Pharmacol 41: 671–676, 1992.
Tajima A, Hata M, Ohta N, Ohtawara Y, Suzuki K, Aso Y: Bredinin treatment in clinical kidney allografting. Transplantation 38: 116–118, 1984.
Gregory CR, Gourley IM, Cain GR, Broaddus TW, Cowgill LD, Willits NH, Patz JD, Ishizaki G: Effects of combination cyclosporine/mizoribine immunosuppression on canine renal allograft recipients. Transplantation 45: 856–859, 1988.
Marumo F, Okubo M, Yokota K, Uchida H, Kumano K, Endo T, Watanabe K, Kashiwagi N: A clinical study of renal transplant patients receiving triple-drug therapycyclosporine A, mizoribine, and prednisolone. Transplant Proc 20 (Suppl 1): 406–409, 1988.
Hayashi R, Suzuki S, Shimatani K, Watanabe H, Kenmochi T, Fukuoka T, Niiya S, Amemiya H: Synergistic effect of cyclosporine and mizoribine on graft survival in canine organ transplantation. Transplant Proc 22: 1676–1678, 1990.
Mita K, Akiyama N, Nagao T, Sugimoto H, Inoue S, Osakabe T, Nakayama Y, Yokota K: Advantages of mizoribine over azathioprine combination therapy with cyclosporine for renal transplantation. Transplant Proc 22: 1679–1681, 1990.
Kokado Y, Ishibahi M, Jiang H, Takahara S, Sonoda T: Low-dose ciclosporin, mizoribine and prednisolone in renal transplantation: a new triple-drug therapy. Clin Transplant 4: 191–197, 1990.
Lee HA, Slapak M, Venkatraman G, Mason J, Digard N, Wise M: Mizoribine as an alternative to azathioprine in triple-therapy immunosuppressant regimens in cadaveric renal transplantation. Transplant Proc 25: 2699–2700, 1993.
Gregory CR, Gourley IM, Cain GR, Patz JD, Imondi KA, Martin JA: Mizoribine serum levels associated with enterotoxicity in the dog. Transplantation 51: 877–881, 1991.
Shiraki K, Ishibashi M, Okuno T, Kokado Y, Takahara S, Yamanishi K, Sonoda T, Takahashi M: Effects of cyclosporine, azathioprine, mizoribine, and prednisolone on replication of human cytomegalovirus. Transplant Proc 22: 1682–1685, 1990.
Morris RE, Hoyt EG, Murphy MP: Mycophenolic acid morpholinoedthylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 22: 1659–1662, 1990.
Allison AC, Almquist SJ, Muller CD, Eugui EM: In vitro immunosuppressive effects of mycophenolic acid and an es-ter pro-drug, RS-61443. Transplant Proc 23 (Suppl 2): 10–14, 1991.
Eugui EM, Mirkovich A, Allison AC: Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents. Transplant Proc 23 (Suppl 2): 15–18, 1991.
Platz KP, Eckhoff DE, Hullet DA, Sollinger HW: RS-61443 studies: review and proposal. Transplant Proc 23 (Suppl 2): 33–35, 1991.
Sollinger HW, Eugui EM, Allison AC: RS-61443: mechanism of action, experimental and early clinical results. CLin Transplant 5: 523–526, 1991.
Eugui EM, Almquist SJ, Muller CD, Allison AC: Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 33: 161–173, 1991.
Eugui EM, Mirkovich A, Allison AC: Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 33: 175–183, 1991.
Hao L, Lafferty KJ, Allison AC, Eugui EM: RS-61443 allows islet allografting and specific tolerance in mice. Transplant Proc 22: 876–879, 1990.
Morris RE, Wang J, Blum JR, Flavin T, Murphy MP, Almquist SJ, Chu N, Tam YL, Kaloostian M, Allison AC, Eugui EM: Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant Proc 23 (Suppl 2): 19–25, 1991.
Platz KP, Sollinger HW, Hullett DA: RS-61443—A new, potent immunosuppressive agent. Transplantation 51: 27–31, 1991.
Knechtle SJ, Wang J, Beesku M, Burlingham WJ, Sollinger HW, Belzer FO: Effect of RS-61443 in preventing rejection in sensitized recipients. Surg Forum 41: 380–381, 1990.
Sollinger HW, Deierhoi MH, Belzer FO, Diethelm AG, Kauffman RS: RS-61443—A phase I clinical trial and pilot rescue study. Transplantation 53: 428–432, 1992.
Deierhoi MH, Solinger HW, Diethelm AG, Belzer FO, Kauffman RS: One-year follow-up results of a phase I trial of mycophenolate mofetil (RS61443) in cadaveric renal transplantation. Transplant Proc 25: 693–694, 1993.
Deierhoi MH, Kauffman RS, Hudson SL, Barber WH, Curtis JJ, Julian BA, Gaston RS, Laskow DA, Diethelm AG: Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center. Ann Surg 217: 476–484, 1993.
Salaman JR, Griffin PJA, Johnson RWG, Kohlhaw K, Land W, Moore R, Pichlmayr R, Sells R: Controlled trial of RS-61443 in renal transplant patients receiving cyclosporine monotherapy. Transplant Proc 25: 695–696, 1993.
Sollinger HW, Belzer FO, Deierhoi MH, Diethelm AG, Gonwa TA, Kauffman RS, Klintmalm GB, McDiiarmid SV, Roberts J, Rosenthal JT, Tomlanovich SJ: RS-61443: rescue therapy in refractory kidney transplant rejection. Transplant Proc 25: 698–699, 1993.
Klintmalm GB, Ascher NL, Busuttil RW, Deierhoi M, Gonwa TA, Kauffman R, McDiarmid S, Poplawski S, Sollinger H, Roberts J: Rs-61443 for treatment—resistant human liver rejection. Transplant Proc 25: 697, 1993.
Simon P, Townsend RM, Harris RR, Jones EA, Jaffe BD: Brequinar sodium: inhibition of dihydrorotic acid dehydrogenase, depletion of pyrimidine pools, and consequent inhibition of immune functions in vitro. Transplant Proc 25 (Suppl 2): 77–80, 1993.
Makowka L, Cramer DV: Brequinar sodium: a new immunosuppressive drug for transplantation. Transplant Sci 2: 50–54, 1992.
Cramer DV, Chapman FA, Jaffee BD, Jones EA, Knoop M, Hreha-Eiras G, Makowka L: The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat. Transplantation 53: 303–308, 1992.
Cramer DV, Chapman FA, Makowka L: Prevention of vascularized allograft and xenograft rejection in rodents by brequinar sodium. Transplant Proc 25 (Suppl 2): 23–28, 1993.
Cosenza CA, Cramer DV, Eiras-Hreha G, Cajulis E, Wang HK, Makowka L: Evaluation of the use of brequinar sodium and cyclosporine combination therapy for preventing rat cardiac allograft rejection. Transplant Proc 25 (Suppl 2): 57–58, 1993.
Makowka L, Tixier D, Chaux A, Hill D, O’Neill P, EirasHreha G, Wu GD, Cunneen S, Cajulis E, Zajac I, Jaffee BD, Chapman FA, Cramer DV: Use of brequinar sodium for preventing cardiac allograft rejection in primates. Transplant Proc 25 (Suppl 2): 48–53, 1993.
Collins BH, Areford ML, Fabian MA, Jaffee BD, Bollinger RR: Brequinar sodium potentiates the effects of cyclosporine in experimental small bowel transplantation. Transplant Proc 25 (Suppl 2): 37–39, 1993.
Stepkowski SM, Kahan BD: Synergistic activity of the triple combination: cyclosporine, rapamycin, and brequinar. Transplant Proc 25 (Suppl 2): 29–31, 1993.
Hullett DA, Sollinger HW: Mycopyhenolate mofetil and brequinar sodium: new immunosuppressive agents. Transplant Proc 25 (Suppl 2): 45–47, 1993.
Yasunaga C, Cramer DV, Cosenz CA, Tuso PJ, Chapman FA, Barnett M, Mu GD, Putnam BA, Makowka L: Effect of brequinar sodium on in vivo antibody production. Transplant Proc 25 (Suppl 2): 40–44, 1993.
Ptachinski RJ, Burckart GJ, Venkataramanan R: Cyclosporine concentration determinations for monitoring and pharmacokinetic studies. J Clin Pharmacol 26: 358–366, 1986.
Lindholm A, Welsh M, Rutzky L, Kahan BD: The adverse impact of high cyclosporine clearance rates on the incidence of acute rejection and graft loss. Transplantation 55: 985–993, 1993.
Meyer MM, Munar M, Udeaja J, Bennett W: Efficacy of area under the curve cyclosporine monitoring in renal transplantation. J Am Soc Nephrol 4: 1306–1315, 1993.
Ritschel WA, Adolph S, Ritschel GB, Schroeder T: Improvement of peroral absorption of cyclosporine A by microemulsions. Methods Find Exp Clin Pharmacol 12: 127134, 1990.
Kovarik JM, Mueller EA, Johnston A, Hitzenberger G, Kutz K: Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. Pharmacotherapy 13: 613617, 1993.
Mueller EA, Kovarik JM, van Brel JB, Lison AE, Kutz K: Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients—a concentration-controlled comparison with the commercial formulation. Transplantation 57: 1178–1182, 1994.
Vonderscher J, Meinzer A: Rational for the development of Sandimmune Neoral. Transplant Proc 26: 2925–2927, 1994.
Holt DW, Mueller EA, Kovarik JM, van Bull JB, Kutz K: The pharmacokinetics of Sandimmune Neoral: a new oral formulation of cyclosporine. Transplant Proc 26: 2935–2939, 1994.
Kahan BD, Dunn J, Fitts C, Van Buren D, Wombolt D, Pollak R, Carson R, Alexander JW, Chang C, Choc M, Wong R: The Neoral formulation: improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients. Transplant Proc 26: 2940–2943, 1994.
Superina RA, Strong DK, Acal LA, DeLuca E: Relative bioavailability of Sandimmune and Sandimmune Neoral in pediatric liver recipients. Transplant Proc 26: 2979–2980, 1994.
Trull AK, Tan KKC, Tan L, Alexander GJM, Jamieson NV: Enhanced absorption of new oral cyclosporin microemulsion formulation, Neoral, in liver transplant recipients with external biliary diversion. Transplant Proc 26: 2977–2978, 1994.
Storck M, Mickley V, Grab C, Steinbach G, Abendroth D: Cyclosporine levels in diabetic (Type I) patients undergoing kidney and pancreas transplantation: role of a new galenic formulation. Transplant Proc 26: 2996–2998, 1994.
Fiocchi R, Mamprin F, Gamba A, Glauber M, Catania S, Cattaneo G, Torre L, Bertocchi C, Ruhrmann R, Colombo D, Binetti G, Ferrazzi P: Pharmacokinetic profile of cyclosporin A in long-term heart transplanted patients treated with a new oral formulation. Transplant Proc 26: 2994–2995, 1994.
Neumayer HH, Farber L, Haller P, Kohnen R, Maibucher A, Schuster A, Vollmer J, Waiser J: Conversion from Sandimmun to Sandimmun Neoral in patients with stable renal allografts: results after one month. Transplant Proc 26: 2944 2988, 1994.
Duncan JI, Thomson AW, Simpson JG, Davidson RJL, Whiting PH: A comparative toxicology study of cyclosporine and Nva-2 cyclosporine in Sprague–Dawley rats. Transplantation 42: 395–399, 1986.
McKenna RM, Szturm K, Jeffrey JR, Rush DN: Inhibition of cytokine production by cyclosporine A and G. Transplantation 47: 343–348, 1989.
Hiestand PC, Traber R, Borel JF: Pharmacological studies with norvaline 2–cyclosporine (SD2 OG 37–325) in comparison with cyclosporin (Sandimmun): a summary. Transplant Proc 26: 2999–3001, 1994.
Hagberg RC, Hoyt EG, Billingham ME, Sibley RK, Scarnes VA, Baldwin JC: Comparison of cyclosporin A and G with and without azathioprine regarding immunosuppressive activity, toxicity, and pharmacokinetics in Lewis rats. J Heart Transplant 7: 359–369, 1988.
Masri MA, Naiem M, Pingle S, Daar AS: Cyclosporine A versus cyclosporine G: a comparative study of survival, hepatotoxicity, nephrotoxicity, and splenic atrophy in BALB/c mice. Transplant Int 1: 13–18, 1988.
Burdmann EA, Andoh TF, Rosen S, Lindsley J, Munar MY, Elzinga LW, Bennett WM: Experimental nephrotoxicity, hepatotoxicity and pharmacokinetics of cyclosporin G versus cyclosporin A. Kidney Int 45: 684–691, 1994.
Huser B, Thiel G, Oberholzer M, Beveridge T, Bianchi L, Mihatsch MJ, Landmann J: The efficacy and tolerability of cyclosporine G in human kidney transplant recipients. Transplantation 54: 65–69, 1992.
Henry ML, Tesi RJ, Elkhammas EA, Ferguson RM: A randomized, prospective, double-blinded study of cyclosporine vs. 0G37–325 in cadaveric renal transplantation—a preliminary report. Transplantation 55: 748–752, 1993.
Hiestand PC, Graber M, Hurtenbach U, Herrmann P, Cammisuli S, Richardson BP, Eberle MK, Donatsch P, Ryffel B, Borel JF: New cyclosporine derivative SD2IMM125: in vitro and in vivo pharmacologic effects and toxicologic evaluation. Transplant Proc 25: 691–692, 1993.
Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, Goto T, Okuhara M, Kohsaka M, Aoki H: FK506, a novel immunosuppressant isolated from a streptomyces. Immunosuppressive effect of FK506 in vitro. J Antibiot 40: 1256–1260, 1987.
Thompson AW: FK-506: profile of an important new immunosuppressant. Transplant Rev 4: 1–13, 1990.
Johansson A, Moller E: Evidence that the immunosuppressive effects of FK-506 and cyclosporine are identical. Transplantation 50: 1001–1007, 1990.
Wood RP, Katz SM, Kahan BD: New immunosuppressive agents. Transplant Sci 1: 34–46, 1991.
Peters DH, Fittow A, Plosker GL, Faulds D: Tacrolimus: a review of its pharmacology and therapeutic potential in hepatic and renal transplantation. Drugs 46: 746–794, 1993.
Bierer BE, Schreiber SL, Burakoff SJ: Mechanisms of immunosuppression by FK506. Preservation of T cell transmembrane signal transduction. Transplantation 49: 1168–1170, 1990.
Bierer BE, Somers PK, Wandless TJ, Burakoff SJ, Schreiber SL: Probing immunosuppressant action with a nonnatural ligand Science 250: 556–559, 1990.
Van Duyne GD, Standaert RF, Karplus PA, Schreiber SL, Clardy J: Atomic structure of FKBP-FK506, an immunophilinimmunosuppressant complex. Science 252: 839–842, 1991.
Suzuki N, Sakane T, Tsunematsu T: Effects of a novel immunosuppressive agent, FK506, on human B cell activation. Clin Exp Immunol 79: 240–245, 1990
Lagodzinski Z, Gorski A, Stepien-Sonpniewska B, Wasik M: Effect of FK506 on B-cell responses. Transplant Proc 23: 94 2943, 1991.
Ochiai T, Nakajima K, Nagata M, Suzuki T, Asano T, Uematsu T, Goto T, Hori S, Kenmochi T, Nakagoori T, Isono K: Effect of a new immunosuppressive agent, FK506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc 19: 1284–1286, 1987.
Murase N, Kim D, Todo S, Cramer DV, Fung JJ, Starzl TE: Suppression of allograft rejection with FK506. Transplantation 50: 186–189, 1990.
Hildebrandt A, Meiser B, Human P, Reichenspurner H, Rose A, Odell J, Reichart B: FK506: short-and long-term treatment after cardiac transplantation in nonhuman primates. Transplant Proc 23: 509–510, 1991.
Starzl TE, Fung J, Jordan M, Shapiro R, Tzakis A, McCauley J, Johnston J, Iwaki Y, Jain A, Alessiani M, Todo S: Kidney transplantation under FK506. JAMA 264: 63–67, 1990.
Japanese FK506 Study Group: Japanese study of FK506 in kidney transplantation: results of an early phase II study. Transplant Proc 23: 3071–3074, 1991.
Fung JJ, Shapiro R, Armitage J, Starzl TE: Influence of FK506 in clinical transplantation. In: AW Thomson, TE Starzl, eds, Immunosuppressive Drugs: Developments in Anti-Rejection Therapy. Edward Arnold, London, pp 121128, 1994.
Jordan ML, Shapiro R, Vivas CA, Scantleburg VP, Darras FS, Carrieri G, McCauley J, Demetris AJ, Randhawa P, Jensen C, Hakala TR, Fung JJ, Starzl TE: FK506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. Transplant Proc 25: 638–640, 1993.
Jordan ML, Shapiro R, Jensen CWP, Scantleburg V, Fung J, Tzakis A, McCauley J, Jain A, Demetris A.1, Randhawa P, Simmons RL, Hakala TR, Starzl TE: FK506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc 23: 3078–3081, 1991.
Tzakis AG, Reyes J, Todo S, Nour B, Shapiro R, Jordan M, McCauley J, Armitage J, Fung JJ, Starzl TE: Two-year experience with FK506 in pediatric patients. Transplant Proc 25: 619–621, 1993.
European FK506 Multicenter Liver Group: Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 344: 423–428, 1994.
The U.S. Multicenter FK506 Liver Study Group: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 331: 1110–1115, 1994.
Klintmalm G: A review of FK506: a new immunosuppressant agent for the prevention and rescue of graft rejection. Transplant Rev 8: 53–63, 1994.
McCauley J: The nephrotoxicity of FK506 as compared with cyclosporine. Curr Opin Nephrol Hypertens 2: 662–669, 1993.
Demetris AJ, Banner B, Fung J, Shapiro R, Jordan M, Starzl TE: Histopathology of human renal allograft rejection under FK506: a comparison with cyclosporine. Transplant Proc 23: 944–946, 1991.
Japanese FK506 Study Group: Japanese study of FK506 on kidney transplantation: results of a late phase II study. Transplant Proc 25: 649–654, 1993.
Eidelman BH, Abu-Elmagd K, Wilson J, Fung JJ, Alessiani M, Jain S, Takaya S, Todo SN, Tzakis A, Van Thiel D, Shannon W, Starzl TE: Neurologic complications of FK506. Transplant Proc 23: 3175–3178, 1991.
Scantleburg V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE: New onset diabetes in FK-506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc 23: 3169–3170, 1991.
Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE: FK-506-associated diabetes mellitus in the pediatric transplant population is a rare complication. Transplant Proc 23: 3171–3172, 1991.
Carroll PB, Boschero AC, Li M-Y, Tzakis AG, Starzl TE, Atwater L: Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. Transplantation 51: 275–278, 1991.
Jindal RM, Popescu I, Emre S, Schwartz ME, Boccagni P, Meneses P, Mor E, Sheiner P, Miller CM: Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506. Transplantation 57: 1395–1397, 1994.
Fung JJ, Alessiani M, Abu-Elmagd K, Todo S, Shapiro R, Tzakis A, Van Thiel D, Armitage J, Jain A, McCauley J, Selby R, Starzl TE: Adverse effects associated with the use of FK506. Transplant Proc 23: 3105–3108, 1991.
Vathsala A, Goto S, Yoshimura N, Stepkowski S, Chou T-C, Kahan BD: The immunosuppressive antagonism of low doses of FK506 and cyclosporine. Transplantation 52: 12 1128, 1991.
Fukuse T, Hirai T, Yokomise H, Hasegawa S, Hirata T, Muro K, Inui K, Hitomi S, Wada H: Combined therapy with FK506 and cyclosporine for canine lung allotransplantation: immunosuppressive effects and blood trough levels. J Heart Lung Transplant 12: 941–947, 1993.
Kahan BD, Chang JY, Sehgal SN: Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. Transplantation 52: 185–191, 1991.
Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH: Distinct mechanism of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 144: 251–258, 1990.
Kahan BD, Gibbons S, Tejpal N, Chou TC, Stepkowski S: Synergistic effect of the rapamycin/cyclosporine combination: median effect analysis of in vitro performances by human T lymphocytes in PHA, CD3 and MLR proliferative and cytotoxicity assays. Transplant Proc 23: 1090–1091, 1991.
Chang JY, Sengal SN, Bansbach CC: FK506 and rapaymcin: novel pharmacological probes of the immune response. Trends Pharmacol Sci 12: 218–223, 1991.
Morris RE: Rapamycins: antifungal, antitumor, antiproliferative and immunosuppressive macrolides. Transplant Rev 6: 39–87, 1992.
Daloze P, Chen H, Luo H, Xu D, Wu J: Rapaymcin’s longterm effect on humoral and cellular immune responses in the rat. Transplant Proc 25: 721–722, 1993.
Kimball PM, Kerman RH, Kahan BD: Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine. Transplantation 51: 486–490, 1991.
Morris RE, Wu J, Shorthouse R: A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. Transplant Proc 22: 1638–1641, 1990.
Collier DSJ, Caine R, Thiru S, Lim S, Pollard SG, Barron P, Dacosta M, White RJ: Rapamycin in experimental renal allografts in dogs and pigs. Transplant Proc 22: 1674–1675, 1990.
Stepkowski SM, Chen H, Daloze P, Kahan BD: Prolongation by rapamycin of heart, kidney, pancreas, and small bowel allograft survival in rats. Transplant Proc 23: 507–508, 1991.
Chen HF, Wu JP, Lu HY, Daloze PM: Reversal of ongoing rejection of allografts by rapamycin. Transplant Proc 23: 2241–2242, 1991.
Wang M, Stepkowski SM, Ferraresso M, Kahan BD: Rapamycin rescue therapy delays rejection of major (MHC) plus minor (non-MHC) histoincompatible heart allografts in rats. Transplantation 54: 704–709, 1992.
Boyle MJ, Kahan BD: Immunosuppressive role of rapamycin in allograft rejection. In: AW Thomson, TE Starzl, eds, Immunosuppressive Drugs: Developments in Anti-Rejection Therapy. Edward Arnold, London, pp 129–140, 1994.
Meiser BM, Billingham ME, Morris RE: Effects of cyclosporine, FK506 and rapamycin on graft vessel disease. Lancet 338: 1297–1298, 1991.
Gregory CR, Pratt RE, Huie P, Shorthouse R, Dzau VJ, Billingham ME, Morris RE: Effect of treatment with cyclosporine, FK506, rapamycin, mycophenolic acid or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. Transplant Proc 25: 770–771, 1993.
Whiting PH, Woo J, Adam BJ, Hasan NU, Davidson RJ, Thomson AW: Toxicity of rapamycin-a comparative and combination study with cyclosporine at immunotherapeutic doses in the rat. Transplantation 52: 203–208, 1991.
Kahan BD, Tejpal N, Gibbons-Stubbers S, Tu Y, Wang M, Stepkowski S, Chou TC: The synergistic interactions in vitro and in vivo of brequinar sodium with cyclosporine or rapamycin alone and in triple combination. Transplantation 55: 894–900, 1993.
Williams JW, Xiao F, Foster PF, Chong A, Sharma S, Bartlett R, Sankarg HN. Immunosuppressive effects of leflunomide in a cardiac allograft model. Transplant Proc 25: 745–746, 1993.
Chong AS-F, Finnegan A, Jiang XL, Gebel H, Sankarg HN, Foster P, Williams JW: Leflunomide, a novel immunosupressive agent: the mechanism of inhibition of T cell proliferation. Transplantation 55: 1361–1366, 1993.
Kuchle CCA, Thoenes GH, Langer KH, Schorlemmer HU, Bartlett RR: Prevention of kidney and skin allograft rejection in rats by leflunomide, a new immunosuppressive agent. Transplant Proc 23: 1083–1086, 1991.
Schorlemmer HU, Seiler FR, Bartlett RR: Prolongation of allogeneic transplanted skin grafts and induction of tolerance by leflunomide, a new immunosuppressive isoxazol derivative. Transplant Proc 25: 763–767, 1993.
Reichenspurner H, Hildebrandt A, Human PA, Boehm DH, Rose AG, Odell JA, Reichart B, Schorlemmer HU: 15deoxyspergualin for induction of graft nonreactivity after cardiac and renal allotransplantation in primates. Transplantation 50: 181–185, 1990.
Waaga AM, Jlrichs K, Krzymanski M, Treumer J, Hansmann ML, Rommel T, Muller-Ruchholtz W: The immunosuppressive agent 15-deoxyspergualin induces tolerance and modulates MHC-antigen expression and interleukin-1 production in the early phase of rat allograft responses. Transplant Proc 22: 1613–1614, 1990.
Valdivia LA, Monden M, Gotoh M, Nakano Y, Tono T, Mori T: Evidence that deoxyspergualin prevents sensitization and first-set cardiac xenograft rejectoion in rats by suppression of antibody formation. Transplantation 50: 132–136, 1990.
Tepper MA, Petty B, Bursuker I, Pasternak RD, Cleaveland J, Spitalny GL, Schacter B: Inhibition of antibody production by the immunosuppressive agent, 15-deoxyspergualin. Transplant Proc 23: 328–331, 1991.
Yuh DD, Morris RE: 15-deoxyspergualin is a more potent and effective immunosuppressant than cyclosporine but does not effectively suppress lymphoproliferation in vivo. Transplant Proc 23: 535–539, 1991.
Gannedahl G, Karlsson-Parra A, Totterman TH, Tufveson G: 15-deoxyspergualin inhibits antibody production in mouse to rat heart transplantation. Transplant Proc 25: 778–780, 1993.
Schorlemmer HU, Dickneite G, Seiler FR: Treatment of acute rejection epsiodes and induction of tolerance in rat skin allotransplantation by 15-deoxyspergualin. Transplant Proc 22: 1626–1630, 1990.
Nemoto K, Hayashi M, Ito J, Saguwara Y, Mae T, Fujil H, ABE F, Takeuchi T: Deoxyspergualin in lethal murine graftversus-host disease. Transplantation 51: 712–715, 1991.
Yabuuchi H, Nakajima Y, Segawa M, Kanehiro H, Murao Y, Hisanaga M, Yoshimura A, Wada T, Nakagawa K, NakanoH: Prominent prolongation of islet xenograft survival in combination therapy with FK 506 and 15-deoxyspergualin. Transplant Proc 23: 859–861, 1991.
Okazaki H, Sato T, Jimbo M, Senga S, Amada N, Oguma S: Prophylatic use of deoxyspergualin in living related renal transplantation. Transplant Proc 23: 1094–1095, 1991.
Koyama I, Amemiya H, Taguchi Y, Wanatage T, Nagashima N, Suzuki S, Omoto R: Prophylatic use of deoxyspergualin in a quadruple immunosuppressive protocol in renal transplantation. Transplant Proc 23: 1096–1098, 1991.
Okazaki H, Sato T, Amada N: Further study of deoxyspergualin prophylaxis in living related renal transplantation. Transplant Proc 25: 772–773, 1993.
Takahashi K, Ota K, Tanabe K, Oba S, Teraoka S, Toma H, Agishi T, Kawaguchi H, Ito K: Effect of a novel immunosuppressive agent, deoxyspergualin, on rejection in kidney transplant recipients. Transplant Proc 22: 1606–1612, 1990.
Amemiya H, Dohi K, Otsubo O, Endo T, Nagano S, Ishibashi M, Hirano T, Sato K, Kurita T, Fukao K: Markedly enhanced therapeutic effect of deoxyspergualin on acute rejection when combined with methylprednisolone in kidney recipients. Transplant Proc 23: 1087–1089, 1991.
Amemiya H, Taguchi Y, Fukao K, Isono K, Ornato R, Ota K, Kosaki M, Takagi H, Oka T, Sonoda T, Orita K, Dohi K: Establishment of rejection therapy with deoxyspergualin by multicentral controlled clinical studies in renal recipients. Transplant Proc 25: 730–733, 1993.
Borg AJ, Ohlman S: 15-deoxyspergualin treatment of graft rejection in man: effect on mononuclear cells. Transplant Int 5: 219–225, 1992.
Ohlman S, Zilg H, Schindel F, Lindholm A: Pharmacokinetics of 15-deoxyspergualin studied in renal transplant patients receiving the drug during graft rejection. Transplant Int 7:510, 1994.
Groth CG, Ohlman S, Ericzon BG, Barkholt L, Reinholt FP: Deoxyspergualin for liver graft rejection. Lancet 336: 626, 1990.
Matas AJ, Gores PK, Kelley SL, Bielefield-Skrokov M, Kinaszezuk M, Gruessner RWG, Najarian JS: Pilot evaluation of 15-deoxyspergualin for refractory acute renal transplant rejection. Clin Transplant 8: 116–119, 1994.
Badger AM, DiMartino MJ, Talmadge JE, Picker DH, Schwartz DA, Dorman JW, Mirabelli CK, Hanna N: Inhibition of animal models of autoimmune disease and the induction of non-specific suppressor cells by SKF 105685 and related azaspiranes. Int J Immunopharmacol 11: 839–846, 1989.
Badger AM, King AG, Talmadge JE, Schwartz DA, Picker DH, Mirabelli CK, Hanna N: Induction of non-specific suppressor cells in normal Lewis rats by a novel azaspirane SKF 105685. J Autoimmunol 3: 485–500, 1990.
Badger AM, Albrightson-Winslow CR, Kupiec-Weglinski JW: SKF 105685: a novel immunosuppressive compound with efficacy in animal models of autoimmunity and transplantation. Transplant Proc 23: 194–195, 1991.
Schmidbauer G, Hancock WW, Badger AM, KupiecWeglinski JW: Induction of nonspecific x-irradition-resistant suppressor cell activity in vivo and prolongation of vascularized allograft survival by SKF 105685, a novel immunomodulatory azaspirane. Transplantation 55: 1236 1243, 1993.
Schmidbauer G, Hancock WW, Badger AM, KupiecWeglinski JW: SKF treatment induces suppressor cell activity and modulates cell adhesion properties in rat recipients of cardiac allografts. Transplant Proc 25: 758–760, 1993.
Fan P-Y, Albrightson CR, Howell DN, Best C, Badger AM, Coffman TM: The azaspirane SKF 105685 ameliorates renal allograft rejection in rats. J Am Soc Nephrol 3: 1680–1685, 1993.
Tax WJM, van de Heijden HMW, Willems HW, Hoitsma AJ, Berden JHM, Capel PJA, Koene RAP: Immunosuppression with monoclonal anti-T3 antibody (WT32) in renal transplantation. Transplant Proc 19: 1905–1907, 1987.
Chatenoud L, Ferran C, Legendre C, Kurile R, Kreis H, Bach JF: Immunological follow-up of renal allograft recipients treated with BMA 031 (anti-TCR) monoclonal antibody. Transplant Proc 22: 1787–1788, 1990.
Dendorfer U, Hillebrand G, Kasper C, Smely S, Weschka M, Hammer C, Racenberg J, Gurland HJ, Land W: Effective prevention of interstitial rejection crises in immunological high risk patients following renal transplantaton: use of high doses of the new monoclonal antibody BMA 031. Transplant Proc 22: 1789–1790, 1990.
Pfeffer PF, Ohlman S, Jakobsen A, Fauchald P, Leivestad T, Tyden G, Flatmark A: A Scandinavian two-center study of BMA031 in steroid-resistant rejection of renal grafts. Transplantation 56: 304–307, 1993.
Schlitt HJ, Kurrle R, Wonigiet K: T cell activation by monoclonal antibody directed to different epitopes on the human T cell receptor/CD3 complex: evidence for two different modes of activation. Eur J Immunol 19: 1649–1655, 1989.
Kurrle R, Kanzy EJ, Racenberg J, Lang W, Seiler FR: BMA 031-a TCR-specific monoclonal antibody for clinical application. Transplant Proc 21: 1017–1019, 1989.
Smely S, Weschka M, Hillebrand G, Dendorfer U, Krombach F, Kurrle R, Land W, Hammer C: Prophylactic use of the new monoclonal antibody BMA 031 in clinical kidney transplantation. Transplant Proc 22: 1785–1786, 1990.
Waid TH, Lucas BA, Amlot P, Janossy G, Yacoub M, Cammisuli S, Jezek D, Rhoades J, Brown S, Thompson JS: TI0B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection. Am J Kidney Dis 14 (Suppl 2): 61–70, 1989.
Waid TH, Lucas BA, Thompson JS, Brown SA, Munch L, Prebeck RJ, Jezek D: Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Transplantation 53: 80–86, 1992.
Waid TH, Lucas BA, Thompson JS, Brown S, Moore D, Amlot P, Janossy G: Treatment of acute cellular kidney allograft rejection with T10B9.1A-31 anti-T-cell monoclonal antibody. Transplant Proc 21: 1778–1784, 1989.
Kirkman RL, Shapiro ME, Carpenter CB, Milford EL, Ramos EL, Tilney NL, Waldmann TA, Zimmerman CE, Strom TB: Early experience with anti-Tac in clinical renal transplantation. Transplant Proc 21: 1766–1768, 1989.
Cantarovich D, LeMauff B, Hourmant M, Giral M, Denis M, Jacques Y, Soulillou JP: Anti-IL2 receptor monoclonal antibody (33B3.1) in prophylaxis of early kidney rejection in humans: a randomized trial versus rabbit antithymocyte globulin. Transplant Proc 21: 1769–1771, 1989.
Cantarovich D, LeMauff B, Hourmant M, Dantal J, Baatard R, Denis M, Jacques Y, Karam G, Paineau J, Soulillou JP: Prevention of acute rejection episodes with an antiinterleukin 2 receptor monoclonal antibody: results after combined pancreas and kidney transplantation. Transplantation 57: 198–203, 1994.
Norman DJ, Bennett WM, Cobanoglu A, Hershberger R, Hosenpud JD, Meyer MM, Misiti J, Ott G, Ratkovec R, Shihab F, Vitow C, Barry JM: Use of OKT4A (a murine monoclonal anti-CD4 antibody) in human organ transplanta-tion: initial clinical experience. Transplant Proc 25: 802–803, 1993.
Morel P, Vincent C, Cordier G, Panaye G, Carosella E, Revillard JP: Anti-CD4 monoclonal antibody administration in renal transplanted patients. Clin Immunol Immunopathol 56: 311–322, 1990.
Reinke P, Volk HD, Miller H, Neuhaus K, Fietze E, Herberger J, Herberger D, Baehr RV, Emmrich F: AntiCD4 therapy of acute rejection in long-term renal allograft recipients. Lancet 338: 702–703, 1991.
Meiser BM, Reiter C, Ebel M, Uberfuhr P, Wenke K, Reichenspurner H, Rieber E, Riethmuller G, Reichart B: A new chimeric monoclonal CD4 antibody for prevention of rejection after heart transplantation. Transplant Proc 24: 1734, 1992.
Marlin SD, Springer TA: Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function associated antigen (LFA1). Cell 51: 813–819, 1987.
Stauton DE, Dustin MI, Springer TA: Functional cloning of ICAM-2, a cell adhesion ligand for LFA1 homologous to ICAM-1. Nature 339: 61–64, 1989.
Dijken PJV, Ghayur T, Mauch P, Down J, Burakoff SJ, Ferrara JLM: Evidence that anti-LFA1 in vivo improves engraftment and survival after allogeneic bone marrow transplantation. Transplantation 49: 882–886, 1990.
Fischer A, Griscelli C, Blanche S, Deist FL, Veber F, Lopez M, Delaage M, Olive D, Mawas C, Janossy G: Prevention of graft failure by anti-LFA1 monoclonal antibody in HLA matched bone marrow transplantation. Lancet 2: 1058–1061, 1986.
Maraninchi D, Mawas C, Reiffers J, Gaspard MH, Laurent G, Stoppa A, Hirn M, Delaage M: Anti-LFA1 monoclonal antibody and bone marrow graft rejection in adults. Lancet 2: 579–580, 1988.
LeMauff B, Hourrmant M, Rougier JP, Hirn M, Dantal J, Baatard R, Cantarovich D, Jacques Y, Soulillou JP: Effect of anti-LFA1 (CD11a) monoclonal antibodies in acute rejection in human kidney transplantation. Transplantation 52: 291–296, 1991.
Haug CE, Colvin RB, Delmonico FL, Auchincloss H, Tolkoff-Rubin N, Preffer FI, Rothlein R, Norris S, Scharschmidt L, Cosimi AB: A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAB in renal allograft recipients. Transplantation 55: 766–772, 1993.
Milford EL, Carpenter CB, Kirkman RL, Tilney NL, Mazoujian G, Strom TB, Lazarus JM, Schlossman SF, Guttmann RD, Lowry R, Rocher L, Campbell DA, Salomon DR, Pfaff WW: Anti-T12 monoclonal antibody therapy of acute renal allograft rejection. Transplant Proc 19: 1910, 1987.
Levin B, Hoppe RT, Collins G, Miller E, Waer M, Bieber G, Girinsky T, Strober S: Treatment of cadaveric renal transplant recipients with total lymphoid irradiation, antithymocyte globulin, and low-dose prednisone. Lancet 2: 1321–1325, 1985.
Vanrenterghem Y, Waer M, Roels L, Michielsen P: A controlled trial comparing pretransplant total lymophoid irradiation versus posttransplant cyclosporine in type I diabetic cadaveric kidney graft recipients: short-term results. Transplant Proc 19: 1542–1543, 1987.
Myburgh JA, Meyers AM, Botha JR, Thompson PD, Smith JA, Browde S, Lakier R: Wide field low-dose total lymphoid irradiation in clinical kidney transplantation. Transplant Proc 19: 1974–1977, 1987.
Strober S, Dhillon M, Schubert M, Holm B, Engleman E, Benike C, Hoppe R, Sibley R, Myburgh JA, Collins G: Acquired immune tolerance to cadaveric renal transplants. N Engl J Med 321: 28–33, 1989.
Molajoni ER, Bachetoni A, Anti P, Poli L, Caricato M, Pretagostini R, Vetere A, Bertoco P, Alfani D, Cortesini R: Eight-year actuarial graft and patient survival of kidney transplants in highly immunized recipients pretreated with total lymphoid irradiation: a single-center experience. Transplant Proc 25: 776–777, 1993.
Monaco AP, Wood ML: Studies of heterologous anti-lymphocyte serum in mice. Optimal cellular antigen for induction of immunologic tolerance with antilymphocyte serum. Transplant Proc 2: 489–496, 1970.
Thomas JM, Carver FM, Foil MB, Pryor WH, Larkin EW, Hall WR, Haisch CE, Thomas JM: Renal allograft tolerance induced with ATG and donor bone marrow in outbred rhesus monkeys. Transplantation 36: 104–106, 1983.
Barber WH, Mankin JA, Laskow DA, Deierhoi MH, Julian BA, Curtis JJ, Diethelm AG: Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation 51: 70–75, 1991.
Salvatierra O, Vincenti F, Amend W, Potter D, Iwaki Y, Opelz G, Terasaki P, Duca R, Cochrum K, Hanes D, Stoney RJ, Feduska NJ: Deliberate donor-specific blood transfusions prior to living related renal transplantation: a new approach. Ann Surg 192: 543–552, 1980.
Alexander JW, First MR, Davies CB, Campbell P, Babcock GF: Donor-specific transfusion-induced tolerance in animals and man: a therapeutic strategy. Transplant Sci 3: 72–75, 1993.
Rubin RJ, Cosimi AB, Hirsch MS, Herrin JT: Effects of antithymocyte globulin on cytomegalovirus infection in renal transplant recipients. Transplantation 31: 143–145, 1981.
Hanto DW, Jendrisak MD, So SKS, McCullough CS, Rush TM, Michalski SM, Phelam D, Mohanakumar T: Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation: results of a single institution prospective randomized trial. Transplantation 57: 377384, 1994.
Cecka JM, Gjertson D, Terasaki PI: Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high risk groups? Transplant Proc 25: 548–549, 1993.
Pfaff WW, Patton PR, Howard RJ, Brunson ME, Ramos EL, Fennell RS, Peterson JC, Scornik JC: Immunosuppression without prophylaxtic antilymphocyte preparations. In: P Terasaki, J Cecka, eds, Clinical Transplants 1992. UCLA Tissue Typing Laboratory, Los Angeles, pp 237–248, 1993.
Curtis JJ, Galla JH, Kotchen TA, Lucas B, McRoberts JW, Luke RG: Prevalence of hypertension in a renal transplant population on alternate-day steroid therapy. Clin Nephrol 5: 123–127, 1976.
Diethelm AG, Sterling WA, Hartley MW, Morgan JM: Alternate-day prednisone therapy in recipients of renal allografts. Arch Surg 111: 867–870, 1976.
Dumler F, Levin NW, Szego G, Vulpetti AT, Preuss LE: Longterm alternate day steroid therapy in renal transplantation. Transplantation 34: 78–82, 1982.
Curtis JJ, Galla JH, Woodf d SY, Lucas BA, Luke RG: Effect of alternate-day pre nisone on plasma lipids in renal transplant recipients. Kidney Int 22: 42–47, 1982.
Hricik DE, Almawi WY, Strom TB: Trends in the use of glucocorticoids in renal transplantation. Transplantation 57: 979–989, 1994.
Kupin W, Venkat KK, Oh HK, Dienst S: Complete replacement of methylprednisolone by azathioprine in cyclosporinetreated primary cadaveric renal transplant recipients. Transplantation 45: 53–55, 1988.
Hricik DE, Whalen CC, Lautman J, Bartucci MR, Moir EJ, Mayes JT, Schulak JA: Withdrawal of steroids after renal transplantation-clinical predictors of outcome. Transplantation 53: 41–45, 1992.
Hricik DE, O’Toole M, Schulak JA, Herson J: Steroid-free, cyclosporine-based immunosuppression after renal transplantation: a meta-analysis of controlled trials. J Am Soc Nephrol 4: 1300–1305, 1993.
Sinclair NRStC: Low-dose steroid therapy in cyclosporinetreated renal transplant recipients with well-functioning grafts. Can Med Assoc J 147: 613–614, 1992.
Hariharan S, Schroeder TJ, Weiskittel P, Alexander JW, First MR: Prednisone withdrawal in HLA identical and one haplotype-matched live-related donor and cadaver renal transplant recipients. Kidney Int 44 (Suppl 43): 30–35, 1993.
Sheriff MHR, Yayha T, Lee HA: Is azathioprine necessary in renal transplantation? Lancet 1: 118–120, 1978.
Schmidt P, Kapsa H, Zazgornik J, Pils P, Balcke P: Renal graft acceptance without azathioprine. Lancet 2: 314, 1978.
Dandavino R, Trunet P, Descamps B, Kreis H: Prolonged withdrawal of azathioprine in kidney transplantation. Transplant Proc 10: 655–657, 1978.
Ozaki A, Iwasaki Y, Miyajima T: Withdrawal of azathioprine after renal transplantation. Transplant Proc 12: 513–514, 1980.
Haesslein HC, Pierce JC, Lee HM, Hume DM: Leukopenia and azathioprine management of renal homotransplantation. Surgery 71: 598–604, 1972.
Woods JE, de Weerd JH, Johnson WJ, Anderson CF: Splenectomy in renal transplantation-influence on azathioprine sensitivity. JAMA 218: 1430–1431, 1972.
Toussaint C, Kinnaert P, Vereerstraeten P, Dupont E, Van Geertruyen J: Azathioprine is necessary in kidney transplantation. Transplantation 27: 145–146, 1979.
Parfrey PS, Hutchinson TA, Lowry RP, Knaack J, Guttmann RD: The role of azathioprine reduction in late renal allograft failure. Transplantation 39: 147–151, 1985.
Starzl TE, Weil III R, Iwatsuki S, Klintmalm G, Schroter GPJ, Koep LJ, Iwaki Y, Terasaki PI, Porter KA: The use of cyclosporin and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet 151: 17–26, 1980.
Kahan BD, Mickey R, Flechner SM, Lorber MI, Wideman CA, Kerman RH, Terasaki P, Van Buren CT: Risk factors for cadaveric donor allograft survival in cyclosporineprednisone-treated recipients. Transplant Proc 19: 1835–1838, 1987.
MacDonald AS, Daloze P, Dandavino R, Jindal S, Bear L, Dossetor JB, Klassen J, Stiller CR, Lockwood B, Reeve CE, and the Canadian Transplant Group: A randomized study of cyclosporine with and without prednisone in renal allograft recipients. Transplant Proc 19: 1865–1872, 1987.
European Multicentre Trial Group: Cyclosporin in cadaveric renal transplantation: one-year followup of a multicentre trial. Lancet 2: 986–989, 1983.
Merion RM, White DJG, Thiru S, Evans DB, Calne RY: Cyclosporine: five years’ experience in cadaver renal transplantation. N Engl J Med 310: 148–154, 1984.
Simmons RL, Canafax DM, Strand M, Ascher NL, Payne WD, Sutherland DER, Najarian JS: Management and prevention of cyclosporine nephrotoxicity after renal transplantation: use of low doses of cyclosporine, azathioprine and prednisone. Transplant Proc 17 (Suppl 1): 266–275, 1985.
Fries D, Hiesse C, Charpentier B, Rieu P, Neyrat N, Cantarovich M, Ouziala, Bellamy J, Benoit G: Triple combination of low-dose cyclosporine, azathioprine and steroids in first cadaver donor renal allografts. Transplant Proc 19: 1911 1914, 1987.
Henry ML, Sommer BG, Ferguson RM: Triple drug therapy: an alternative regimen in renal transplantation. Transplant Proc 19: 1920–1921, 1987.
Terasaki PI, Cecka JM, Lim E, Takemoto S, Cho Y, Gjertson D, Ogura K, Koyama H, Mitsuishi Y, Yuge J, Cohn M: Overview. In: P Terasaki, ed, Clinical Transplants 1991. UCLA Tissue Typing Laboratory, Los Angeles, pp 409–430, 1992.
Ihorogood J, van Houwelingen JC, van Rood JJ, Zantvoort FA, Scheuder GMT, Persijn GG: Factors contributing to longterm kidney graft survival in Eurotransplant. Transplantation 54: 152–158, 1992.
Opelz G: Collaborative Transplant Study: 10-year report. Transplant Proc 24: 2342–2355, 1992.
European multicenter trial of cyclosporine in renal transplantation: 10-year follow-up. Transplant Proc 25:527–529, 1993.
Opelz G: Superior long-term kidney graft survival in patients on maintenance immunosuppression with cyclosporine and azathioprine. Transplant Proc 25: 1289–1290, 1993.
Myers BD, Newton L, Oyer P: The case against the indefinite use of cyclosporine. Transplant Proc 23: 41–42, 1991.
Hoitsma AJ, Van Lier HJJ, Wetzels JFM, Berden JHM, Koene RAP: Cyclosporin treatment with conversion after three months versus conventional immunosuppression in renal allograft recipients. Lancet 1: 584–586, 1987.
Morris PJ, Allen RD, Thompson JF, Chapman JR, Ting A, Dunnill MS, Wood RFM: Cyclosporin conversion versus conventional immunosuppression: long-term followup and histological evaluation. Lancet 1: 586–591, 1987.
Kasiske BL, Heim-Duthoy K, Ma JZ: Elective cyclosporine withdrawal after renal transplantation: a meta-analysis. JAMA 269: 395–400, 1993.
Cecka JM, Terasaki PI: Early rejection episodes. In: P Terasaki, ed, Clinical Transplants 1989. UCLA Tissue Typing Laboratory, Los Angeles, pp 425–434, 1990.
Sumrani N, Delaney V, Daskalakis P, Hong JH, Cacciarelli TV, Sommer BG: The detrimental effect of early rejection on long-term renal allograft outcome. Transplant Proc 24: 1750 1752, 1992.
Koyama H, Cecka JM: Rejection episodes. In: PI Terasaki, JM Cecka, eds, Clinical Transplants 1992. UCLA Tissue Typing Laboratory, Los Angeles, pp 391–403, 1993.
Basadonna GP, Matas AJ, Gillingham KJ, Payne WD, Dunn DL, Sutherland DER, Gores PF, Gruessner RWG, Najarian JS: Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 55: 993–995, 1993.
Tesi RJ, Henry ML, Eldhammas EA, Ferguson RM: Predictors of long-term primary cadaveric renal transplant survival. Clin Transplant 7: 345–352, 1993.
Stiller CR, Opelz G: Should cyclosporine be continued indefinitely? Transplant Proc 23: 36–40, 1991.
Sanders CE, Curtis JJ, Julian BA, Gaston RS, Jones PA, Laskow DA, Deierhoi MH, Barber WH, Phil D, Diethelm AG: Tapering or discontinuing cyclosporine for financial reasons-A single-center experience. Am J Kidney Dis 21: 9–15, 1993.
Thiel G, Mihatsch M, Landmann J, Hermle M, Brunner FP, Harder F: Is cyclosporin-A induced nephrotoxicity in recipients of renal allograft progressive? Transplant Proc 17 (Suppl 1): 169–178, 1985.
Tilney NL, Milford EL, Carpenter CB, Lazarus JM, Strom TB, Kirkman RL: Long-term results of cyclosporine treatment in renal transplantation. Transplant Proc 18: 179–185, 1986.
Snider J, Francis DMA, Kincaid-Smith P, Walker RG: Longterm graft survival and renal function in cyclosporin-treated renal allograft recipients: lack of evidence of nephrotoxicity. Clin Transplant 7: 25–27, 1993.
Lewis R, Podbielski J, Sprayberry S, Munsell M, Katz S, Rubin M, Kimball P, Van Buren CT, Kerman R, Kahan B: Stability of renal allograft glomerular filtration rate associated with long-term use of cyclosporine A. Transplantation 55: 1014–1017, 1993.
Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, Gruessner R, Najarian JS: Risk factors for chronic rejection in renal allograft recipients. Transplantation 55: 752–757, 1993.
Hong CD, Kapoor BS, First MR, Pollak VE, Alexander JW: Fractional excretion of sodium after renal transplantation. Kidney Int 16: 167–178, 1979.
Sethi K, First MR, Pesce AJ, Fidler JP, Pollak VE: Proteinuria following renal transplantation. Nephron 18:4959, 1977.
Woloszczuk W, Troppmair J, Leiter E: Relationshop of interferon-gamma and neopterin levels during stimulation with alloantigens in vivo and in vitro. Transplantation 41: 716719, 1986.
Maury CPJ, Teppo AM: Serum immunoreactive interleukin 1 in renal transplant recipients. Transplantation 45: 143–147, 1988.
McKenna RM, Rush DN, Bakkestad-Legare P, Jeffrey JR: Interleukin 2, interferon, and lymphotoxin in renal transplant recipients. Transplantation 45: 76–81, 1988.
van Oers MHJ, van der Heyden AA, Aaren LA: Interleukin 6 in serum and urine of renal transplant recipients. Clin Exp Immunol 71: 314–319, 1988.
Colvin RB, Preffer FI, Fuller TC, Brown MC, Ip SH, Kung PC, Cosimi AB: A critical analysis of serum and urine interleukin-2 receptor assays in renal allograft recipients. Transplantation 48: 800–805, 1989.
McLaughlin PJ, Aikawa A, Davies HM: Evaluation of sequential plasma and urinary tumor necrosis factor alpha levels in renal allograft recipients. Transplantation 51: 1225 1229, 1991.
Schroeder TJ, Helling T, McKenna RM, Rush D, Jeffrey JR, Brewer B, Martin LA, Traylor D, Fisher RA, First MR, Muth KL: A multicenter study to evaluate a novel assay for quantitation of a soluble interleukin 2 receptor in renal transplant recipients. Transplantation 53: 34–40, 1992.
Maury CPJ, Teppo AM, Eklund B, Ahonen J: Serum amyloid A protein: a sensitive indicator of renal allograft rejection in humans. Transplantation 36: 501–504, 1983.
Edwards LC, Helderman JH, Hamm LL, Ludwin D, Gailiunas P, Hull AR: Noninvasive monitoring of renal
Cohen DJ, Benvenisty AI, Meyer E, Hardy MA: Serum C-reactive protein concentrations in cyclosporine-treated renal allograft recipients. Transplantation 45: 919–922, 1988.
Schumann GB, Burleson RL: Importance of urine cytology in renal transplantation. Transplantation 23: 186–188, 1977.
Fidler JP, Dajani F, First MR, Munda R, Alexander JW: Value of urine cytology in renal transplantation. Transplantation 26: 133–135, 1978.
Dooper IMM, Bogman MJT, Hoitsma AJ, Maas CN, Vooijs PG, Koene RAP: Immunocytology of urinary sediments as a method of differentiating acute rejection from other causes of declining renal graft function. Transplantation 52: 266–271, 1991.
von Willebrand E: Fine-needle aspiration cytology of human renal allografts. Clin Immunol Immunopathol 17: 309–322, 1980.
Hayry P, von Willebrand E: Monitoring of human renal allograft rejection with fine-needle aspiration cytology. Scand J Immunol 13: 87–97, 1981.
Belitsky P, Campbell J, Gupta R: Serial biopsy controlled evaluation of fine needle aspiration in renal allograft rejection. Lab Invest 53: 580–585, 1985.
Sheth S: Evaluation of acute renal transplant rejection with duplex sonography. In: JF Burdick, LC Racusen, K Solez, GM Williams, eds, Kidney Transplant Rejection: Diagnosis and Treatment. Marcel Dekker, New York, pp 459–470, 1992.
Rigsby CM, Taylor KW, Weltin GG, Garnes PB, Bia M, Princethol RA, Kashgarian M, Flye WM: Renal allografts in acute rejection: evaluation using duplex sonography. Radiology 158: 375–378, 1986.
Rifkin MD, Needleman L, Pasto ME, Kurtz AB, Foy PM, McGlynn E, Canino C, Baltarowich OH, Pennell RB, Goldberg BB: Evaluation of renal transplant rejection by Doppler examination. Value of the resistive index. Am J Radiol 148: 759–762, 1987.
Camargo EE, Sostre S: Radionuclides in the evaluation of kidney transplant rejection. In: JF Burdick, LC Racusen, K Solez, GM Williams, eds, Kidney Transplant Rejection: Diagnosis and Treatment. Marcel Dekker, New York, pp 471–485, 1992.
Dubovsky EV, Russel CD: Radionuclide evaluation of renal transplants. Semin Nucl Med 18: 181–198, 1988.
Tempany CMC, Yang A: Magnetic resonance imaging and magnetic resonance spectroscopy. In: JF Burdick, LC Racusen, K Solez, GM Williams, eds, Kidney Transplant Rejection: Diagnosis and Treatment. Marcel Dekker, New York, pp 487–502, 1992.
Geisinger MA, Risius B, Jordan ML, Zelch M, Novick AC, George CR: Magnetic resonance imaging of renal transplants. Am J Radiol 143: 1229–1234, 1984.
Mahoney MC, Racadio JM, Merhar GL, First MR: Safety and efficacy of kidney transplant biopsy: Tru-cut needle vs sonographically guided biopty gun. Am J Roentgen 160: 325326, 1993.
Solez K, Axelsen RA, Benediktsson H, Burdick JF, Cohen AH, Colvin RB, Croker BP, Droz D, Dunnill MS, Halloran PF, Hayry P, Jennette JC, Keown PA, Marcussen N, Mihatsch MJ, Morozumi K, Racusen LC, Ramos EL, Rosen S, Sachs DH, Salomon DR, Sanfilippo F, Verani R, von Willebrand E, Yamaguchi Y: International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classifications of kidney transplant pathology. Kidney Int 44: 411–422, 1993.
Rush D, Jeffrey J, Gough J: Protocol biopsies in stable renal transplant patients under triple immunosuppression: results at 6 months. Transplant Proc 26: 25–76, 1994.
Goodwin WE, Kaufman JJ, Mims MM, Turner RD, Glassock R, Goldman R, Maxwell MM: Human renal transplantation: clinical experience with six cases of renal homotransplantion. J Urol 89: 13–24, 1963.
Kauffman HM, Stromstad SA, Sampson D, Stawicki AT: Randomized steroid therapy of human kidney transplant rejection. Transplant Proc 11: 36–38, 1979.
Park GD, Bartucci M, Smith MC: High-versus low-dose methylprednisolone for acute rejection episodes in renal transplantation. Nephron 36: 80–83, 1984.
Mussche MM, Ringoir SMG, Lameire NH: High intravenous doses of methylprednisolone for acute cadaveric renal allograft rejection. Nephron 16: 287–291, 1976.
Gray D, Shepherd H, Daar A, Oliver DO, Morris PJ: Oral versus intravenous high-dose steroid treatment of renal allograft rejection. Lancet 1: 117–118, 1978.
Orta-Sibu N, Chantler C, Bewick M, Haycock G: Comparison of high-dose intravenous methylprednisolone with low-dose oral prednisolone in acute renal allograft rejection in children. Br Med J 285: 258–260, 1982.
Shield CF, Cosimi AB, Tolkoff-Rubin N, Rubin RH, Herrin J, Russel PS: Use of antilymphocyte globulin for reversal of acute rejection. Transplantation 28: 461–464, 1979.
Nowygrod R, Appel G, Hardy MA: Use of ATG for reversal of acute allograft rejection. Transplant Proc 13: 469–472, 1981.
Hoitsma AJ, Reekers P, Kreftenberg JG, van Lier HJJ, Capel PJA, Koene RAP: Treatment of acute rejection of cadaveric renal allografts with rabbit antithymocyte globulin. Transplantation 33: 12–16, 1982.
Broyer M, Niaudet P, Bijaoui, Gagnadoux MF: Treatment of acute rejection crisis by antilymphocyte globulins: a randomized prospective study in pediatric kidney transplant recipients. Transplant Proc 19: 1886–1888, 1987.
Hardy MA, Nowygrod R, Erlberg A, Appel G: Use of ATG in treatment of steroid-resistent rejection. Transplantation 29: 162–164, 1980.
Light JA, Alijani MR, Biggers JA, Oddenino K, Reinmuth B: Antilymphocyte globulin (ALG) reverses irreversible allograft rejection. Transplant Proc 13: 475–481, 1981.
Griffin PJA, Williams GT, Salaman JR: Antilymphocyte globulin for the treatment of steroid non-responsive acute renal allograft rejection. Clin Nephrol 21: 115–117, 1984.
Matas AJ, Tellis VA, Quinn T, Glichlick D, Soberman R, Weiss R, Karwa G, Veith FJ: ALG treatment of steroid-resistant rejection in patients receiving cyclosporine. Transplantation 41: 579–583, 1986.
Veremis SA, Maddux MS, Pollak R, Kline SS, Mozes MF: Alternative antirejection treatment with steroids or antilymphoblast globulin in renal transplant patients receiving cyclosporine. Transplant Proc 19: 1893–1895, 1987.
Deierhoi MH, Barber WH, Curtis JJ, Julian BA, Luke RB, Hudson S, Barger BO, Diethelm AG: Treatment of acute rejection by monoclonals. A comparison of OKT3 monoclonal antibody and corticosteroids in the treatment of acute renal allograft rejection. Am J Kidney Dis 11: 86–89, 1988.
Tesi RJ, Elkhammas EA, Henry ML, Ferguson RM: OKT3 for primary therapy of the first rejection episode in kidney transplants. Transplantation 55: 1023–1029, 1993.
Cosimi AB, Burton RC, Colvin RB, Goldstein G, Delmonico FL, LaQuaglia MP, Tolkoff-Rubin N, Rubin RH, Herrin JT, Russell PS: Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32: 535–539, 1981.
Alamartine E, Bellakoul R, Berthoux F: Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts. Transplant Proc 26: 273–274, 1994.
Anderson P, Schroeder TJ, Hariharan S, First MR: Incidence of post-transplant lymphoproliferative disease in OKT3 treated renal transplant recipients. Clin Transplant 7: 582–585, 1993.
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
First, M.R. (1998). Immunosuppression and Treatment of Rejection. In: Suki, W.N., Massry, S.G. (eds) Suki and Massry’s THERAPY OF RENAL DISEASES AND RELATED DISORDERS. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-6632-5_65
Download citation
DOI: https://doi.org/10.1007/978-1-4757-6632-5_65
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-6634-9
Online ISBN: 978-1-4757-6632-5
eBook Packages: Springer Book Archive